A 24-Week, Phase IIa, Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA)

By sjmartinez • February 15, 2023

Khanna D, Denton CP, Furst DE, Mayes MD, Matucci-Cerinic M, Smith V, de Vries D, Ford P, Bauer Y, Randall MJ, Ebrahimpoor M, Kupcsik L, Stiers PJ, Deberdt L, Prasad N, Lim S, Pujuguet P, Ahmed S. A 24-Week, Phase IIa, Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA). Arthritis Rheumatol. 2023 Feb 14. doi: 10.1002/art.42477. Epub ahead of print. PMID: 36787101.

Tags: Publications, Rheumatology

Specific targeting of cancer cell mitochondria with a malaria drug improves pancreatic cancer outcome

Ou Y, Lim A, Wang R, Mir N, Calsavara VF, Wang Q, Zhang Y, Pandol SJ, Edderkaoui M. Specific targeting of cancer cell mitochondria with[...]

Real-World Management of Chronic Myelogenous Leukemia in an Underserved Patient Cohort at a Los Angeles Safety-Net Health System: Tyrosine Kinase Inhibitor Treatment Patterns and Outcomes From 2015 to 2024

Zheng D, Nold T, Ramakrishnan N, Kim K, Tomassetti S. Real-World Management of Chronic Myelogenous Leukemia in an Underserved Patient Cohort at a Los Angeles[...]

Building families-Implementing balanced sexual and reproductive health: A Joint IFFS and ISA Scientific Statement

Liu PY, Mocanu E, Giudice L, Horton M, Nigdelis MP, Perheentupa A, Sansone A, Corona G, Gianaroli L, Goulis DG. Building families-Implementing balanced sexual and[...]